Yochai Wolf, PhD
Project Title
Improving current mRNA-based CAR-T cells for sustained cancer Immunotherapeutics
Named Grant
Funded in Partnership With The Barbara and Fred Kort Foundation
About the Investigator
Dr. Yochai Wolf is a dedicated cancer researcher at the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center. He holds a PhD in Immunology and has spent over a decade exploring innovative treatments for aggressive cancers. With a special focus on immune-based therapies, Dr. Wolf is working to advance science and bring hope to patients with difficult-to-treat cancers like melanoma.
About the Research
Melanoma, one of the most aggressive skin cancers, remains difficult to treat when it spreads to other parts of the body. A promising treatment approach, called CAR-T cell therapy, uses a patient’s own immune cells to target and destroy cancer. However, while successful in blood cancers, this therapy faces challenges in solid tumors like melanoma, including poor delivery to the tumor and reduced effectiveness over time.
Dr. Wolf is developing a next-generation CAR-T cell therapy specifically designed for melanoma. By using a cutting-edge technique involving messenger RNA (mRNA), this therapy allows temporary and highly controlled activation of the CAR-T cells. This avoids common side effects, such as premature exhaustion of the immune cells, while enhancing their ability to target melanoma.
The project also aims to improve how CAR-T cells reach melanoma tumors and survive within the cancer’s hostile environment. By fine-tuning the genetic instructions delivered to the immune cells, Dr. Wolf hopes to create a safer, more effective treatment for patients.
This research has the potential to transform melanoma therapy, providing a new option for patients who currently have few effective treatments. The findings may also pave the way for broader applications of mRNA-based CAR-T therapies in other cancers.
